cyrilzakka/clinical-trials huggingface dataset:
Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

Purpose: To show early feasibility of magnetocardiography (MCG) to identify coronary Cardiac positron emission tomography (PET) is the preferred non-invasive tests to assess for CAV and incorporation of quantitative myocardial blood flow (MBF) assessment improves diagnostic accuracy. Based on ISHLT criteria, the following have been proposed for diagnosis of CAV by PET:

Diagnosing CAV by PET with quantitative myocardial blood flow (MBF) 3 PET CAV 0: Normal perfusion with normal global stress (\> 1.7 mL/min/g)

PET CAV 1: Normal perfusion with abnormal global stress MBF (\<1.7 mL/min/g and ejection fraction \>45%) OR Single vessel perfusion defect with normal global stress MBF.

PET CAV 2/3: Normal perfusion with abnormal global stress MBF (\<1.7 mL/min/g) and ejection fraction \< 45% OR Single vessel perfusion defect with abnormal global stress MBF (\<1.7 mL/min/g) OR Multivessel perfusion defects

With these diagnostic criteria, PET CAV 0 has been shown to have a high negative predictive value for moderate to severe CAV by invasive coronary angiography, and PET CAV 2/3 has been shown to have a high positive predictive value for moderate to severe CAV and is associated with adverse events.

This study further examines the feasibility of MCG in identifying CAV in adult heart transplant recipients and compares those results to the current non-invasive standard using PET CAV scores. This will help determine whether MCG is a potential test for regular surveillance of CAV in transplant recipients.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years of age at the time of enrollment

Willing to provide written informed consent

Completed cardiac PET within the last 2 weeks

No changes to medication or intervention since the PET was completed

Exclusion Criteria:

* Patients unable to fit into device

Patients unable to lie supine for 5 minutes

Patients with implanted ferromagnetic objects above the costal margin of the rib cage (implanted pacemakers, cardioverter/defibrillators, infusion pumps, and/or neuro stimulators).

NOTE: Sternotomy wires stents are acceptable

Implanted pacemakers or cardioverter/defibrillators

Implanted infusion pumps and/or neuro stimulators

Severe claustrophobia
Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.

Emergence agitation after sevoflurane anesthesia is still a problem needed to be solved.The aim of the study is to delineate the effect of caudal magnesium sulfate in children undergoing lower abdominal surgery to prevent postoperative emergence agitation.

Emergency agitation is considered one of the postoperative complication after sevoflurane anesthesia.In the enrollment of this study,children undergoing lower abdominal surgery will be enrolled in one of two groups.BM group, receive caudal magnesium sulfate 50 mg beside the conventional bupivacaine in the caudal space in ,B group, addition of 1 ml of normal saline0.9% to bupivacine .Monitoring of the postoperative emergence agitation by different emergence agitation scores with monitoring of sedation score.Detection of expected postoperative complications as nausea and vomiting.

Eligibility Criteria:
Inclusion Criteria:

* children undergoing lower abdominal surgery for hernia repair/orchiopexy in Ain Shams University ASA physical status I under sevoflurane anesthesia.
* age from 1-6 years.

Exclusion Criteria:

* children with developmental delay
* neurological disorder.
* psychological disorder
* difficult airway
* hyperactive airway disease
* contraindication to caudal block(sacral abnormality,bleeding disorder).
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects must be willing and able to give written informed consent.
2. Confirmed acute symptomatic DVT, i.e., proximal vein or extensive calf-vein thrombosis, involving at least the upper third part of the deep calf veins (trifurcation area) without concomitant symptomatic PE.
3. Women and men, ages 18 (or legal age of consent) to 90. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 1 week after the study in such a manner that the risk of pregnancy is minimized.

WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal \[defined as amenorrhea for 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35mIU/mL\]. Even women who are using oral, implanted or, injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 24 hours prior to the start of study medication.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding.
2. Women with a positive pregnancy test on enrollment or prior to study drug administration.
3. More than 24 hours pre-randomization treatment with therapeutic dosages of unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or more than a single starting dose of vitamin K antagonist (VKA) prior to randomization.
4. Uncontrolled hypertension: systolic blood pressure \> 200 mm Hg or diastolic blood pressure \> 110 mm Hg.
5. Creatinine clearance \< 30 mL/min
6. Impaired liver function (ALT \> 3 x ULN)
7. Use of ASA \> 165 mg/day
8. WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 1 week after the study.
9. Azole antifungals (e.g., ketoconazole), HIV protease inhibitors (e.g., ritonavir) and macrolide antibiotics (e.g., erythromycin).

NOTE: topical azole antifungal agents are permitted.
Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients with Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.


Eligibility Criteria:
Inclusion Criteria:

* glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness

Exclusion Criteria:

* age\<18 years
* unable to read, understand and sign the written informed consent
* unable to perform visual field test
* advanced glaucoma with C/D\>0.7
* other causes of optic neuropathies
* retinal or macular diseases
* lens or corneal opacities
* spherical refractive defect \>± 6D
* cylindric refractive defect \>± 3D
Role of Point of Care Ultrasound in Endotracheal Tube Placement

Role of point of care ultrasound in endotracheal tube placement in children

Role of point of care ultrasound in confirmation of endotracheal tube placement in children

Eligibility Criteria:
Inclusion Criteria:

* Children below 18 years needing endotracheal intubation.

Exclusion Criteria:

* Age more than 18 years.
* Patients with significant neck or lung pathology.
* Patients with elective intubation
Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness

The purpose of this research is to develop patient-centered palliative care interventions to improve patient-provider communication and Quality of Life (QoL) of ethnic and racial minority patients living with life-limiting illnesses. Eliciting personal experiences is an effective way for patients to communicate their cultural values and beliefs. This study will assess how to integrate the patients' personal experience narratives into the electronic health record (EHR). The primary hypothesis is that the implementation of a patient-centered intervention to elicit personal experiences that are included in the EHR will improve patient-provider communication and patients' QoL.

Racial and ethnic minority patients with a Life Limiting Illnes (LLI) in the United States are underserved in many ways, including quality of palliative care. Specific disparities have been reported in palliative care for minority patients, including sub-optimal patient-provider communication and resulting lower QoL. A potential approach to improve communication is to elicit patients' personal narratives that address their cultural or spiritual values and beliefs, and include them in the EHR. The objective of this observational study is to assess the feasibility and efficacy of a palliative care nursing intervention designed to 1) identify barriers and facilitators for eliciting and recording relevant narratives from the perspectives of the key stakeholders: minority patients with LLI; 2) to conduct usability testing, applying a user-system-environment evaluation process to determine essential requirements for integration of the patient-centered narratives into the EHR; and 3) identify barriers and facilitators of integration of the patient's narrative into daily workflow from the perspectives of key stakeholders: acute care bedside nurse.

Eligibility Criteria:
Inclusion Criteria: Patients

* 18 years of age or older
* able to read English
* capable of giving informed consent
* self-identifying as part of a racial or ethnic minority
* diagnosed with at least one LLI. The operational definition of LLI eligible for this study includes the following diagnoses:

  1. metastatic solid cancer or inoperable lung cancer;
  2. COPD with FEV1 values \< 35% predicted or oxygen dependence;
  3. New York Heart Association Class III or IV heart failure (CHF).

Inclusion criteria: Nurse

* 18 years of age or older
* Confirm verbally that they were involved in the care of a patient who is participating in the storytelling intervention
Interferential Current and Therapeutic Exercise Program in Chronic Neck Pain

Objectives: To analyze the number of sessions needed to achieve a positive impact after combining interferential current therapy and therapeutic exercise, compared with therapeutic exercise alone, on self-reported pain, disability and range of motion in subjects with chronic neck pain.

Design: A randomized, single-blind, controlled trial. Subjects: Patients between 18 and 65 years old, with idiopathic chronic neck pain.

Methods: The experimental group who will perform a combined treatment using Interferential current therapy and therapeutic exercise for two weeks. The control group will receive the same program of therapeutic exercise during the same period of time.


Eligibility Criteria:
Inclusion Criteria:

* Nonspecific mechanical neck pain (chronic neck pain diagnosed by a physician)
* Age between 18 and 65 years old
* Both males and females
* Non apprehension to electrotherapy (determined by the Personal Psychological Apprehension scale- EAPP)
* Self-reported pain higher than 2 in the 11-point Numeric Pain Rating Scale

Exclusion Criteria:

* Metallic implants in the vertebral column
* Apprehension to electrotherapy (a score \>45 points in EAPP)
* Cervicogenic headache
* Cervicogenic Dizziness
* Neck pain associated with neurological deficits
* Unexplained fever
* Cervical surgery associated to persistent pain
* Specific diagnostics (cervical myelopathy, cervical stenosis, osteomyopathy)
* Other diagnostics such as visceral pain referred to the neck or non-cervical cause.
* Involvement in litigation
* Manual treatment for the neck-shoulder area in the last month before data collection
Antidiabetic Potiential of Moringa and Dom Extract

The Antidiabetic potential of Hyphaene thebaica fruits and Moringa oleifera leaves will be investigated in diabetic patients (type 2). The patients will be maintained on tea of both drugs for 6 weeks. The fasting blood glucose levels of patients will be checked on a daily basis. Other blood biomarkers will be also reported such as insulin concentration, Lipid profile, liver enzymes, c-peptide and glycated hemoglobin


Eligibility Criteria:
Inclusion Criteria:

* diabetic patients type 2

Exclusion Criteria:

* liver failure
* heart failure
* renal failure
Clinical Effects of Ozone Therapy in Cervical Disc Hernia

The aim of the study is to evaluate the clinical effects of Ozone-oxygen therapy as therapeutic substance for nucleolysis application in the patients with cervical disc hernia who had chronic pain and weakness on the neck, shoulders and arms

This is a retrospective, single-center study that is going to be conducted from November 2013 to May 2016 on patients visiting the pain clinic of the hospital who were treated with Ozone-oxygen therapy for cervical discogenic or radicular pain.

Data collected from medical record forms and electronic medical record system of the hospital were used in the retrospective analysis of medical data with regard to age, gender, complications.

A resident who has not involved in the study interviewed each patient by telephone on the follow up to collect the related information.

Eligibility Criteria:
Inclusion Criteria:

* continuous radicular pain radiating to the upper limb, with a duration ≥8 weeks and an intensity \>4/10 as rated by the patient on a visual analog scale (VAS)
* resistant to appropriate conservative treatment combining antiinflammatory drugs, and confirmed by imaging with CT or MRI of a herniated disc putting pressure on a nerve root consistent with the clinical pain.

Exclusion Criteria:

* history of surgery at the cervical spine, contraindication to percutaneous chemonucleolysis (coagulopathy or infection), imaging results that did not support the clinical results, the presence of a herniated disc excluded or calcified on imaging, possible interference with pain evaluation due to any medical condition or treatment, involvement of incomplete data collection
Examination and Treatment of Elderly After a Fall

Falls and injurious falls are common among elderly people. The aim of the study is to test a model of multifactorial fall intervention in a Danish population of elderly sustaining a fall. Focus is on prevention of further falls, patients views on fall prevention and a cost-effectiveness analysis.


Eligibility Criteria:
Inclusion Criteria:

* 65 years old or older
* Having been treated in emergency department or submitted to hospital after a fall
* Living in the Glostrup area.

Exclusion Criteria:

* Fall due to strong external force, new apoplexia cerebri, epileptic seizure, alcohol intoxication.
* Known cognitive impairment
* Not able to walk prior to fall
* Living in institution
* Planned geriatric intervention.
Low Back Pain and Motor Control in Soccer Players

Identification of the effects of low back pain and motor control influence on soccer players performance.

At least 60 volunteer athletes who playing soccer at least 3 years, not away from field more than 2 weeks, 16 years and older are planned to include this study. All participating athletes in this study will be signed an informed consent form then their demographic information will be recorded. To evaluate disability due to low back pain, musculoskeletal problems and the willingness to participate in sports will be used the Oswestry Disability index, the Nordic Musculoskeletal System questionnaire and the Sport Motivation Scale-2, respectively. The motor control levels of the athletes will be assessed with the motor control test battery (MKTB), the core stability with the Sahrmann's core stability test, core muscles endurance with the sport-specific endurance plank test and side bridge endurance test, the static balance with the stand stork test, the dynamic balance with the lower quadrant y balance test, postural changes with the Corbin Posture Rating Scale, the agility with the T test, speed and coordination with 4-10 shuttle run test, explosive force with long jump test, the kinetic chain with the functional movement screen.

Eligibility Criteria:
Inclusion Criteria:

* Be over 16 years old,
* Participating in the soccer training for at least three years,
* Soccer players who have not stayed away from their sport for more than two weeks

Exclusion Criteria:

* Any history of orthopedic or neurological injury or pain that may interfere with normal football training or competition during assessment
* History of spine/lower and upper extremity surgery,
* Structural deformities such as scoliosis and kyphosis,
* Having trap neuropathy
* Soccer players who had injuries other than chronic low back pain in the last 6 months will be excluded from the study.
Probiotics in Elderly Patients With Medical Conditions

Study of efficacy of probiotic in older patients with multiple co-morbidites and constipation

Background and aims:

Probiotics are known to have a beneficial effect on the management of constipation. Thus, the current study objective was to evaluate the impact of a microbial cell preparation (MCP) (Hexbio®; comprising Bifidobacterium and Lactobacillus strains) on stool frequency, consistency, and constipation-related symptoms in elderly patients with multiple chronic medical conditions.

Eligibility Criteria:
Inclusion Criteria:

-clinical diagnosis of constipation

Exclusion Criteria:

* Parkinson's disease,
* spinal cord lesions
* post radiation strictures
* on calcium supplements of greater than 1,500 mg per day
* immune-deficiency
* critical illness
Propofol for Prophylaxis of Morphine Induced Pruritis in Caesarean Section

the goal of this randomized clinical trial is to find the optimum sub hypnotic dose of iv propofol that prevents the incidence of itching induced from intrathecal morphine used in spinal anesthesia in caesarean section operation. the main questions it aim to answer are the number of patients complained of pruritus in the first 24 hours post operative period and the severity of the pruritus. participants will be divided into 4 groups. 1st group receives 0 mg of propofol , 2nd receives 10 mg , 3rd receives 20 mg and the 4th receives 30 mg.


Eligibility Criteria:
Inclusion Criteria:

1. The study is scheduled for women undergoing elective caesarean section under spinal anesthesia.
2. The subject is ≥ 20 years and ≤ 40 years.
3. No obvious abnormalities in preoperative ECG, blood routine, electrolytes, and other tests.
4. ASA class 1-2.

Exclusion Criteria:

* Patients who had a known allergy to propofol, morphine, or bupivacaine.
* Those with preexisting pruritus caused by pregnancy, a coexisting skin disorder, or other pruritogenic systemic diseases.
* Patients with a contraindication to spinal anaesthesia
* Failed block
* Need of extra sedation intra-operative
* Positive history for asthma or COPD.
* Patient refusal
Transapical Beating-Heart Septal Myectomy in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of nonobstructive hypertrophic cardiomyopathy. This is a prospective, single-arm, single-center study.

Medical therapy is first recommended for patients with nonobstructive hypertrophic cardiomyopathy administrated at onset of heart failure symptoms. As the disease progresses, patients with global ejection fraction \< 50% should be evaluated with respect to eligibility and motivation for heart transplant. However, for those with preserved ejection fraction and drug-refractory heart failure symptoms, there is still no optimal therapy. Some patients with increased left atrial volume and/or diastolic dysfunction can be recognized as a result of excessive myocardial hypertrophy, and the septal resection for these patients may be beneficial. However, conventional septal myectomy is hindered by the demanding expertise that is needed to sufficient resection of hypertrophied septal myocardium while guarantee safety. To increase the visualization and minimize the surgical injury of conventional septal myectomy, we have invented a novel beating-heart myectomy device. Through a mini-thoractomy, septal myectomy could be accomplished via a transapical access in the beating heart using the beating-heart myectomy device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular morphology and hemodynamics are evaluated each time after resection. Multiple resections are performed to tailor sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries. After transapical beating-heart septal myectomy, patients are scheduled to be seen for follow-up visits at discharge (about 7 days post operation) and 3 months.

Eligibility Criteria:
Inclusion Criteria:

1. Patients whose maximal ventricular septal wall thickness ≥ 15 mm.
2. Patients with heart function of New York Heart Association ≥ class II.
3. Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies.
4. Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form

Exclusion Criteria:

1. Patients who were pregnant.
2. Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-heart surgery.
3. Patients who had severe heart failure with left ventricle ejection fraction \< 40%.
4. Patients whose estimated life expectancy \< 12 m.
5. Patient who were non-compliant.
6. Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.